Medication overuse headache

被引:3
|
作者
Green, Mark W. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
关键词
chronic daily headache; gepants; management; medication overuse headache; migraine; psychiatric comorbidity; risk factors; NITRIC-OXIDE PATHWAY; CHRONIC MIGRAINE; FOLLOW-UP; RISK-FACTORS; PHARMACOLOGICAL-TREATMENT; PSYCHIATRIC COMORBIDITY; TRANSFORMED MIGRAINE; DETOXIFICATION; PREVALENCE; SENSITIZATION;
D O I
10.1097/WCO.0000000000000925
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review Medication overuse headache (MOH)is a disabling problem worldwide with areas of controversy regarding its cause. This article reviews the recent ideas regarding the development of this disorder and its effective management. Recent findings It has been proposed that all acute migraine medications can lead to MOH, with differences in the propensity of different agents to cause the problem. Early data suggests that gepants, which are small-molecule calcitonin gene-related peptide antagonists used for the acute treatment of migraine, may be an exception. Recent studies show that practitioners and the general public are still largely unaware of the problem of medication overuse and its damaging effects. MOH is an accepted concept of an increase in headaches driven by the frequent administration of acute antimigraine drugs. The impressions of providers, and studies documenting the concept may be flawed. Although it is likely that MOH does occur, and restricting the amount of acute medications is necessary to prevent it, it is also possible that increasing amounts of acute medications are simply a reflection of poorly controlled headaches, rather than a cause. Objective markers need to be developed to identify those who have MOH, which does not include all with chronic migraine, and to use these markers in diagnosis and management, particularly in those patients where the frequent acute drugs might only be a reflection of frequent headaches, rather than a cause.
引用
收藏
页码:378 / 383
页数:6
相关论文
共 50 条
  • [31] Medication-overuse headache
    Katsarava, Zaza
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 400 - 400
  • [32] Medication overuse headache in Scandinavia
    Jensen, R.
    Bendtsen, L.
    [J]. CEPHALALGIA, 2008, 28 (11) : 1237 - 1239
  • [33] Treatment of medication overuse headache
    Madsen, S. K.
    Munksgaard, S. B.
    Wienecke, T.
    [J]. CEPHALALGIA, 2015, 35 : 130 - 130
  • [34] Medication-overuse headache
    Wakerley, Benjamin R.
    [J]. PRACTICAL NEUROLOGY, 2019, 19 (05) : 399 - 403
  • [35] Medication overuse headache in Taiwan
    Wang, S-J
    Fuh, J-L
    [J]. CEPHALALGIA, 2008, 28 (11) : 1240 - 1242
  • [36] Medication overuse headache disability
    Kristoffersen ES
    Grande RB
    Aaseth K
    [J]. 中华物理医学与康复杂志, 2018, 40 (09) : 711 - 711
  • [37] Medication overuse headache in India
    Ravishankar, K.
    [J]. CEPHALALGIA, 2008, 28 (11) : 1223 - 1226
  • [38] Medication overuse headache in Germany
    Katsarava, Z.
    Diener, H-C
    [J]. CEPHALALGIA, 2008, 28 (11) : 1221 - 1222
  • [39] Medication overuse headache - Response
    Haag, Gunther
    [J]. EXPERT OPINION ON DRUG SAFETY, 2007, 6 (02) : 97 - 98
  • [40] Medication overuse headache in Spain
    Pascual, J.
    Mateos, V.
    Gracia, M.
    Lainez, J. M.
    [J]. CEPHALALGIA, 2008, 28 (11) : 1234 - 1236